Overview

Effectiveness of Oral Boldo in Women With Overactive Bladder

Status:
Enrolling by invitation
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
The objective of this clinical trial is to know if boldo oral powder capsules works well in the management of urinary symptoms in women with overactive bladder. The main questions it aims to answer are: - Is boldo supplementation safe? - Does boldo improve urinary parameters and body stability? 5 participants will be treated with an oral antimuscarinic (oxybutynin) and supplemented with oral spray bolus. The urinary chart will be applied to measure urinary frequency and voiding intervals. In addition, urinary symptoms and the level of discomfort they generate will be measured. Finally, the MiniBest test will be applied using a portable device which acts as an inertial sensor to record the movements made. For comparative purposes, 5 women who will only be treated with the oral antimuscarinic (oxybutynin) will be measured to see if there are significant differences between the medication alone versus the supplemented medication.
Phase:
Phase 1
Details
Lead Sponsor:
Universidad de Valparaiso
Collaborator:
Uro Medical Corporation
Treatments:
Oxybutynin